Contemporary Approaches to Kinase Lead Generation
The Learning and Evolution of Medicinal Chemistry against Kinase Targets
Non-Protein Kinases as Therapeutic Targets
The Drug Discovery and Development of Kinase Inhibitors Outside of Oncology
Allosteric Activators of Glucokinase (GK) for the Treatment of Type 2 Diabetes
Subject Index
Publication details
About this book
Kinase inhibition remains an area of significant interest across academia and in the pharmaceutical industry. There are now many marketed drugs which target kinases and a significant number of compounds are currently in various stages of clinical development. Although there have been a number of publications on kinase inhibition, this is the first to examine the future opportunities and challenges in targeting this important family of enzymes. The book is forward-looking and focuses on a number of key areas for kinase inhibition over the coming years.
Author information
Richard A Ward and Frederick W Goldberg have both been working at AstraZeneca in Alderley Park for over 5 years. Richard Ward is a Computational Chemist and Frederick Goldberg is a Medicinal Chemist. They have worked on a significant number of kinase projects and are named on various kinase-related papers and patents and have both presented externally on the subject.